. has announced that it will be limiting its treatment for West Nile virus
encephalitis to immunocompetent patients only, where it has posted a 100% success rate.
Ten out of ten patients, including 4 over the age of 70, responded completely to GenoMed's treatment. The only failure since late August, 2003 when the trial began was a young woman with chronic leukemia treated last September.
So far this April, 31 people have downloaded GenoMed's West Nile virus
trial document. These include 4 physicians; 3 public health officers, including one from Manitoba, Canada and one from Arizona; 2 people from blood banks and 2 more from hospitals.
In addition, 6 patients with chronic residual disease after getting West Nile virus
encephalitis last summer have signed up for GenoMed's trial. One patient with right leg paralysis who has been on GenoMed's treatment during the winter has recovered nearly complete function of his right leg.
GenoMed's patent-pending protocol uses blood-pressure drugs that are safe and already familiar to most physicians. They're carried in every drug store. The protocol, developed by Dr. David Moskowitz, the Company’s Chairman, CEO and Chief Medical Officer, is based on the theory that brain inflammation and death result from an over-response by the patient’s immune system to the West Nile virus. GenoMed’s protocol gently suppresses the immune system at an early step in its activation. The results of Dr. Moskowitz’s first eight patients will be published soon in a peer-reviewed medical journal.
If GenoMed's current 100% cure rate for patients who aren't immunosuppressed holds up, GenoMed hopes to prevent all deaths and cases of paralysis from West Nile virus
encephalitis this season. Immunosuppressed patients include those with AIDS, those taking chemotherapy for cancer, and organ transplant recipients. GenoMed's treatment approach is already known not to work for this group.
For the general population, GenoMed recommends beginning its treatment protocol once a person develops fever and flu-like symptoms after a mosquito bite.
GenoMed hopes to eliminate the threat of West Nile virus
from the general population on the 50th anniversary of the famous 1954 polio field trials which ended the threat of polio in the U.S. For more information, click on the "West Nile trial" button at http://www.genomedics.com
Dr. Moskowitz is a Harvard- and Oxford-educated physician, who trained for seven years in Internal Medicine, Biochemistry, and Nephrology at Washington University School of Medicine in St. Louis before spending 11 years on the faculty of St. Louis University School of Medicine. He is a noted pioneer in the field of medical genomics, and has been recognized for his groundbreaking treatment of diseases associated with the angiotensin I-converting enzyme, such as chronic renal failure due to hypertension or type II diabetes
. Dr. Moskowitz’s research on viruses, including West Nile virus, avian influenza ("bird flu"), and SARS, are regarded as innovative approaches for otherwise incurable diseases.